CD274 and neoplasm: Previous research shows that the immune system can be re-stimulated by blocking PD-L1 expression via the MAPK pathway to induce an anti-tumor reaction (31), indicating that PD-1/PD-L1 monoclonal antibodies have the potential to treat malignancies (Figure 1).